Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 2/20 | 0.62 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.62 |
| ▸ | CCR1 | P32246 | 2/20 | 0.55 |
| ▸ | CCR5 | P51681 | 2/20 | 0.55 |
| ▸ | CCR8 | P51685 | 2/20 | 0.55 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13700995 | 0.85 | PSMD14 (0.62) | PSMD14COPS5CCR1CCR5CCR8 | |
| SCHEMBL26523568 | 0.85 | PSMD14 (0.58) | PSMD14COPS5CCR1CCR5CCR8 | |
| SCHEMBL16248304 | 0.81 | NCF1 (0.52) | PSMD14COPS5NCF1PARP1L3MBTL1 | |
| SCHEMBL7757756 | 0.80 | NCF1 (0.55) | PSMD14COPS5NCF1PARP1NR1H2 | |
| SCHEMBL30604782 | 0.80 | NR4A2 (0.56) | PSMD14COPS5NCF1PARP1NR1H2 | |
| SCHEMBL2876594 | 0.80 | NR4A2 (0.56) | PSMD14COPS5NCF1PARP1NR1H2 | |
| SCHEMBL29862680 | 0.80 | NCF1 (0.51) | PSMD14COPS5NCF1PARP1NR1H2 | |
| SCHEMBL2876591 | 0.80 | NCF1 (0.51) | PSMD14COPS5NCF1PARP1L3MBTL1 | |
| SCHEMBL317787 | 0.80 | NCF1 (0.51) | PSMD14COPS5CCR1CCR8NCF1 | |
| SCHEMBL30880479 | 0.80 | NCF1 (0.51) | PSMD14COPS5CCR1CCR8NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20200054643-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | VANDERBILT UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| EP-2616460-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMA CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2013137479-A1 | DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7247756-B2 | 1,4-disubstituted benzenes as insecticides | BAYER CROPSCIENCE AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-7247756-B2 | 1,4-disubstituted benzenes as insecticides | BAYER CROPSCIENCE AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-5589484-A | TREATMENT OF HELICOBACTER INFECTIONS, ANTIULCER | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-12-31 | — | — | US | disclosed |
| EP-0666855-B1 | 4-QUINOLINYL DERIVATIVES WITH ANTI-HELICOBACTER ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 1996-09-18 | — | — | EP | disclosed |
| EP-0666855-A1 | 4-QUINOLINYL DERIVATIVES WITH ANTI-HELICOBACTER ACTIVITY. | JANSSEN PHARMACEUTICA NV (BE) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994010164-A1 | 4-QUINOLINYL DERIVATIVES WITH ANTI-HELICOBACTER ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | PSMD14 3353/4885COPS5 3101/4885CCR1 1131/4885 |
| US-20200054643-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | BMP1, BMP4, BMPR2 | PSMD14 1894/4885COPS5 695/4885CCR1 2172/4885 |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | PSMD14 3104/4885COPS5 2274/4885CCR1 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.